Illumina expands portfolio, 5/14
May 2014—Illumina is making available new products that can be applied directly to the discovery and translation of genomic variation in blood and tissue associated with cancer.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Monoclonal SOX10 antibody, 5/14
May 2014—Biocare Medical released a mouse monoclonal SOX10 antibody. SOX10 is expressed in 97 to 100 percent of desmoplastic and spindle cell melanomas and in 100 percent of nevi.
Serological pipettes, 5/14
May 2014—295-Eppendorf-03-14Eppendorf introduced a series of Eppendorf Serological Pipets for cell culture applications.
Multianalyte quality controls, 4/14
April 2014—Bio-Rad Laboratories has a comprehensive line of multianalyte quality controls now available in Siemens Dimension Vista vials for use on Siemens Dimension Vista Intelligent Lab Systems.
New CLSI editions: M100-S24, eM100, 4/14
April 2014—The Clinical and Laboratory Standards Institute released a new edition of its document M100-S24: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, which provides updated tables for the CLSI antimicrobial susceptibility testing standards M02-A11, M07-A9, and M11-A8.
Horizon, Desktop Genetics to collaborate, 4/14
April 2014—Horizon Discovery entered into a collaboration agreement with Desktop Genetics for development of a CRISPR design platform. Horizon will use the platform to identify the best guide-RNAs in the human genome for each gene editing task, as part of its GENESIS suite of gene editing technologies.
CMV DNA linearity panel, 4/14
April 2014—SeraCare Life Sciences is offering a nine-member panel made from serial dilutions of a cultured virus with established reactivity for CMV DNA called the CMV DNA AccuSpan Linearity Panel.
Horizon-Haplogen agreement, 4/14
April 2014—Horizon Discovery signed a worldwide distribution agreement with Haplogen in which customers can access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. This is the first time Horizon will distribute another company’s products.
Nuclea partners with AccuGenomics, Nuvera, 4/14
April 2014—Nuclea signed development deals with AccuGenomics and Nuvera Biosciences that will include validating two new assays in the treatment of chronic myeloid leukemia and breast cancer.
Automated pipetting systems, 4/14
April 2014—Eppendorf North America added five models to its epMotion range of automated pipetting systems. The epMotion 5075 system uses Eppendorf’s epBlue software and an intuitive software assistant concept that can be easily programmed and requires only initial training for new users.